N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible

被引:170
作者
Heiskanen, Annamari
Satomaa, Tero
Tiitinen, Sari
Laitinen, Anita
Mannelin, Sirkka
Impola, Ulla
Mikkola, Milla
Olsson, Cia
Miller-Podraza, Halina
Blomqvist, Maria
Olonen, Anne
Salo, Hanna
Lehenkari, Petri
Tuuri, Timo
Otonkoski, Timo
Natunen, Jari
Saarinen, Juhani
Laine, Jarmo
机构
[1] Finnish Red Cross Blood Serv, Dept Res & Dev, Helsinki 00310, Finland
[2] Glykos Finland Ltd, Helsinki, Finland
[3] Univ Helsinki, Biomedicum Helsinki, Helsinki, Finland
[4] Family Federat Finland, Infertil Clin, Helsinki, Finland
[5] Gothenburg Univ, Dept Med Chem & Cell Biol, Inst Biomed, Gothenburg, Sweden
[6] Univ Oulu, Clin Res Ctr, Dept Surg, Oulu, Finland
[7] Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, Helsinki, Finland
关键词
stem cell; xenoantigen; N-glycolylneuraminic acid; clinical trial;
D O I
10.1634/stemcells.2006-0444
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Human embryonic and mesenchymal stem cell therapies may offer significant benefit to a large number of patients. Recently, however, human embryonic stem cell lines cultured on mouse feeder cells were reported to be contaminated by the xeno-carbohydrate N-glycolylneuraminic acid (Neu5Gc) and considered potentially unfit for human therapy. To determine the extent of the problem of Neu5Gc contamination for the development of stem cell therapies, we investigated whether it also occurs in cells cultured on human feeder cells and in mesenchymal stem cells, what are the sources of contamination, and whether the contamination is reversible. We found that N-glycolylneuraminic acid was present in embryonic stem cells cultured on human feeder cells, correlating with the presence of Neu5Gc in components of the commercial serum replacement culture medium. Similar contamination occurred in mesenchymal stem cells cultured in the presence of fetal bovine serum. The results suggest that the Neu5Gc is present in both glycoprotein and lipid-linked glycans, as detected by mass spectrometric analysis and monoclonal antibody staining, respectively. Significantly, the contamination was largely reversible in the progeny of both cell types, suggesting that decontaminated cells may be derived from existing stem cell lines. Although major complications have not been reported in the clinical trials with mesenchymal stem cells exposed to fetal bovine serum, the immunogenic contamination may potentially be reflected in the viability and efficacy of the transplanted cells and thus bias the published results. Definition of safe culture conditions for stem cells is essential for future development of cellular therapies.
引用
收藏
页码:197 / 202
页数:6
相关论文
共 25 条
  • [21] Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells
    Sotiropoulou, Panagiota A.
    Perez, Sonia A.
    Salagianni, Maria
    Baxevanis, Constantin N.
    Papamichail, Michael
    [J]. STEM CELLS, 2006, 24 (02) : 462 - 471
  • [22] Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid
    Tangvoranuntakul, P
    Gagneux, P
    Diaz, S
    Bardor, M
    Varki, N
    Varki, A
    Muchmore, E
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (21) : 12045 - 12050
  • [23] Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy
    Tuschong, L
    Soenen, SL
    Blaese, RM
    Candotti, F
    Muul, LM
    [J]. HUMAN GENE THERAPY, 2002, 13 (13) : 1605 - 1610
  • [24] Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids
    Vazquez, AM
    Alfonso, M
    Lanne, B
    Karlsson, KA
    Carr, A
    Barroso, O
    Fernandez, LE
    Rengifo, E
    Lanio, ME
    Alvarez, C
    Zeuthen, J
    Perez, R
    [J]. HYBRIDOMA, 1995, 14 (06): : 551 - 556
  • [25] Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum
    Zhu, A
    Hurst, R
    [J]. XENOTRANSPLANTATION, 2002, 9 (06) : 376 - 381